Drug Trial Radar · NCT05383209
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Sep 28, 2022
Primary completion
Feb 12, 2024
Study completion May 6, 2024
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
Conditions
- Nonproliferative Diabetic Retinopathy
Interventions
EYP-1901Drug
EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.
Sham IVTOther
Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36Time frame: Baseline (Day 1) and Week 36
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
EyePoint Investigative Site
Phoenix, Arizona
EyePoint Investigative Site
Huntington Beach, California
EyePoint Investigative Site
Oxnard, California
EyePoint Investigative Site
Palm Desert, California
EyePoint Investigative Site
Pasadena, California
EyePoint Investigative Site
Poway, California
EyePoint Investigative Site
Sacramento, California
EyePoint Investigative Site
Danbury, Connecticut
EyePoint Investigative Site
Clearwater, Florida
EyePoint Investigative Site
Melbourne, Florida
EyePoint Investigative Site
Miami, Florida
EyePoint Investigative Site
Winter Haven, Florida
EyePoint Investigative Site
Lemont, Illinois
EyePoint Investigative Site
Indianapolis, Indiana
EyePoint Investigative Site
Lenexa, Kansas
EyePoint Investigative Site
Baltimore, Maryland
EyePoint Investigative Site
Hagerstown, Maryland
EyePoint Investigative Site
Springfield, Massachusetts
EyePoint Investigative Site
Reno, Nevada
EyePoint Investigative Site
Bloomfield, New Jersey
EyePoint Investigative Site
Toms River, New Jersey
EyePoint Investigative Site
Great Neck, New York
EyePoint Investigative Site
Erie, Pennsylvania
EyePoint Investigative Site
Florence, South Carolina
EyePoint Investigative Site
Ladson, South Carolina
EyePoint Investigative Site
Rapid City, South Dakota
EyePoint Investigative Site
Germantown, Tennessee
EyePoint Investigative Site
Abilene, Texas
EyePoint Investigative Site
Austin, Texas
EyePoint Investigative Site
Houston, Texas
EyePoint Investigative Site
McAllen, Texas
EyePoint Investigative Site
Plano, Texas
EyePoint Investigative Site
San Antonio, Texas
EyePoint Investigative Site
The Woodlands, Texas
EyePoint Investigative Site
Lynchburg, Virginia
EyePoint Investigative Site
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.